Search | Clinical Trials Finder

Conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU
Interventions: SLAM + SOC, SOC; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Clinton Township, Michigan

Conditions: Diabetic Foot Ulcer
Interventions: Podimetrics SmartMat; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard Care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Sylmar, California • Miami, Florida + 13 more

Conditions: Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer
Interventions: Blue Drop Foot Scanner; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Clinton Township, Michigan

Conditions: Diabetic Foot Ulcers
Interventions: Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle; Drug
Lead sponsor: OcuNexus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more

Conditions: Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Interventions: ELU42 Topical Spray; Drug
Lead sponsor: Eluciderm Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: O'Fallon, Illinois • Springfield, Illinois • Oradell, New Jersey + 1 more

Conditions: Diabetic Foot Ulcers
Interventions: NEOX®CORD 1K, standard of care; Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more

Conditions: Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions: Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Pathologic Processes, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Disease, Diabetic Angiopathies, Vascular Diseases, Cardiovascular Diseases, Leg Ulcer, Skin Ulcer, Skin Diseases, Diabetes Complications, Diabetic Neuropathies, Foot Diseases, Diabetic Foot, Foot Ulcer, Diabetes Mellitus, Type 2, Ulcer, Foot Ulcer Unhealed
Interventions: Standard of Care - DFU, AM/Single - DFU, AM/Double - DFU, Standard of Care - VLU, AM/Single - VLU, AM/Double - VLU; Other
Lead sponsor: C5 Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Diabetic Foot Ulcer
Interventions: Esmolol hydrochloride, Placebo gel; Drug
Lead sponsor: Novalead Pharma Private Limited; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetic Foot Ulcer
Interventions: glucose control nutritional shake, nutrition education; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Wounds and Injuries, Burns, Mohs Surgery, Diabetic Foot Ulcer Mixed, Venous Leg Ulcer, Non-healing Wound, Trauma Injury, Injury and Wounds, Degloving Injuries, Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions: Various types of wound care treatments; Combination Product
Lead sponsor: Siddhey LLC; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 8 more

Conditions: Diabetic Foot Ulcers
Interventions: Tissue, Control; Other
Lead sponsor: Osiris Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more

Conditions: Diabetes, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Wound, Diabetic
Interventions: Observational; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Miami, Florida + 3 more

Conditions: Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions: EscharEx (EX-02 formulation); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Synthetic Hybrid-Scale Fiber Matrix, Standard of Care, Living Cellular Skin Substitute; Device
Lead sponsor: Acera Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Vista, California • Jacksonville, Florida • Miami Beach, Florida + 3 more

Conditions: Diabetic Foot Ulcer
Interventions: COMS One device, Sham device; Device
Lead sponsor: Piomic Medical; Industry
Eligibility: 22 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: FoundationDRS Solo, Standard of Care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Diabetic Foot Ulcer (DFU), Amnio-Maxx
Interventions: Amnio-Maxx® Dual Layer Amnion Patch, Standard of Care (Investigator Choice); Biological · Other
Lead sponsor: Royal Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Burbank, California • Miami, Florida • Stone Mountain, Georgia + 5 more

Conditions: Diabetic Foot Ulcer
Interventions: Amnion-Intermediate-Chorion, Standard of Care (SOC); Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Santa Rosa, California • Jacksonville, Florida • Chicago, Illinois + 5 more

Conditions: Foot Ulcer, Diabetic
Interventions: Wound Dressing; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Montgomery, Alabama • Castro Valley, California • Bay Pines, Florida + 3 more

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Interventions: an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers; Drug · Other
Lead sponsor: Ayu, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetic Foot Ulcer, Lower Extremity Wound
Interventions: DermACELL AWM; Other
Lead sponsor: LifeNet Health; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Fresno, California • Rocky Mount, North Carolina

Search by objective public record fields.

Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care Versus Standard of Care

Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

The Effects of Nutrition Supplementation and Education on the Healing of Diabetic Foot Ulcer (DFU)

Clinical Registry Collecting Real World Evidence on Wound Care Treatments

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

TEWL Biomarker Study for Diabetic Foot Ulcer Recurrence

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)

A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue

DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers